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ABSTRACT
NMR was used to investigate the reaction of cis- and trans-[RuC12(DMSO)4] with
the antiviral drug acyclovir, a guanine derivative containing the acyclic (2-
hydroxo)ethoxymethyl pendant linked to N(9). Studies were performed in aqueous
solutions at ambient temperature and at 37
o C, and at various molar ratios. Both isomers
yielded two compounds, a monoadduct and a bisadduct, the relative yields being dependent
upon the metal to ligand concentration ratios. The products derived from the two Ru
isomers displayed identical NMR spectra, suggesting that they have the same coordination
environment, however the rate of formation ofthe monoadduct was higher in the case of the
trans isomer than in the case of the cis isomer, while the rate of conversion of the
monoadduct into the bisadduct appeared to be similar in both cases. As a consequence in
the case of the trans isomer there is accumulation of monoadduct in the early stage of the
reaction, whose concentration afterwards decreases with the progress of the reaction. As
for platinum, also for ruthenium the preferred binding site s N(7) of the purine base,
however, in the case of ruthenium a discrete amount of bisadduct is formed even in the
presence of an excess of metallic substrate with respect to the acyclovir ligand; under
similar conditions a platinum substrate would have given, nearly exclusively, the
monoadduct.
INTRODUCTION
Cisplatin, cis-[PtClz(NH)], is one of the most widely used drugs in cancer therapy
1 ], however the appearance of severe side-effects, the drug resistance which develops after
a prolonged treatment, and the limited spectrum of activity has led scientists to search for
new antcancer metal based drugs. Ruthenium complexes are among those which have
displayed a great potential for medical applications. In particular cis- and trans-
[RuClz(DMSO)4], two neutral octahedral Ru(II) compounds, possess significant antitumor
activity and a remarkable antimetastatic activity in some murme tumor models [2-4]. The
cis isomer has one O-bonded and three facial S-bonded DMSO molecules, while in the trans
isomer, all four DMSO molecules are S-bonded. The trans isomer is markedly more toxic
and reactive than the cis isomer [3, 5, 6]. In vivo and in vitro experiments showed that both
isomers interact with DNA [7, 8] and preferential interaction with adjacent guanines was
found upon treatment with pBR 322 DNA [9]. As for the platinum complexes, also for
ruthenium the target atom of the guanine base appears to be N(7). Apart from the abo.ve
mentioned compounds, also other ruthenium compounds have proved to be acuve
antitumor drugs and one of them, NAMI-A, has entered clinical trials as an antimetastatic
agent 10].
In previous papers we investigated the reaction of platinum compounds with the
antiviral drug acyclovir [11-13]; a guanosine analog characterized by having an acyclic
residue [a (2-hydroxy)ethoxymethyl group] linked to N(9). The scope was that of
synthesizing multifunctional drugs in which either the anticancer activity of the platinum
moiety, or the antiviral activity of the acyclovir residue could be enhanced. In some
occasions interesting results, particularly regarding the antitumor activity, were obtained
[14,
A similar investigation has now been performed on two ruthenium substrates and the
results are reported herein.
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MATERIALS AND METHODS
Cis- and trans-[RuC12(DMSO)4] were synthesized and recrystallized as previously
retorted [5.16]. Acyclovir (Sigma) was used with no further purification. The ’H (250.13
1VfHz) and 3C NMR (62.90 MHz) spectra of the ligand and the complexes were obtained
on a BRUKER WM-250 spectrometer in D20 (99.90% D) solutions using DSS as internal
reference. The main parameters used for 3C NMR were: 64k data domain size, 13889 Hz
spectral width, 0.5s relaxation delay, and 28500 scans.
RESULTS AND DISCUSSION
The chemical behavior of cis- and trans-[RuC12(DMSO)4] (abbreviated as cis-Ru
trans-Ru, respectively) in aqueous solutions has been extensively investigated [5, 7, 81.
Once dissolved in water the cis isomer releases its O-bonded DMSO molecule to give
cis,fac-[RuCl(H20)(DMSO)], which then slowly (in about 3h at 37 C) substitutes a
chloride ion with water, leaing to cis,fac-[RuCl(H20)2(DMSO)]+. In contrast trans-
[RuC12(DMSO)4] immediately replaces two neighboring DMSO molecules with water,
generating trans, cis,cis-[RuC12(H20)(DMSO)2], which, slowly (about 8 h at 37 C)
exchanges one chlorine atom to give the cationic complexfac,cis-[RuCl(H20)(DMSO)2]+.
The reactions of cis- and trans-[RuC12(DMSO)4] with acyclovir (ACV, Scheme l)
were performed at different molar ratios (r ACV:Ru 1:1, 2:1, and 1:1.25), at room
temperature and at 37 C in unbuffered water solutions. The fully deuterated metal
complexes were also used under identical experimental conditions in order to avoid
overlapping of the methyl protons of the DMSO molecules with the proton resonances of
the acyclovir alkyl groups.
NMR spectroscopy was employed both to characterize the metal complexes and to
monitor the time course of the reaction.
CH2,. O/CH2.. .. OH
1’ 2’ CH’2
3’
Scheme 1" Schematic drawing ofACV showing also the numbering scheme
Reaction of trans-[RuCl(DMSO)4] with acyclovir
When trans-[RuC12(DMSO)4] reacts with an equimolar solution of acyclovir, at room
temperature, two different reaction products, I and II, are formed. The time profile of the
reaction is depicted in Fig. 1 a. Complex I dominates during the first two hours of reaction.
Integration otthe H8 signals reveals that 60% of the overall species is present as complex I
after 30 minutes. For longer reaction time complex I starts decreasing while a new product,
compound II, continuously increases reaching its maximum concentration after 24 h. The
free acyclovir concentration decreases dramatically during the first hour of reaction. In the
final solution, no free acyclovir is detected whereas complex I accounts for ca. 40% of the
reaction products and complex II for about 60%. Unreacted solvolysis products of trans-
[RuC12(DMSO)4] are also present.
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Figure 1. Time dependence of the concentration of different species in the reaction of trans-
Ru with ACV (a, ACV:trans-Ru 1:1; b, ACV:trans-Ru 2:1; c, ACV:trans-Ru 1:1.25)
performed in water solution at room temperature. The concentrations were determined by
ntegration of the peak areas of the aromatic region (H8 ofACV) in the HNMR spectra.
Using an acyclovir to trans-[RuC12(DMSO)4] molar ratio of 2:1, the same products,
compounds I and II, observed in the previous experiment are formed. However the time
profile of the product formation (Fig. l b) differs from that observed when using the
reactants in a 1:1 molar ratio. The concentration of complex I again increases during the first
30 minutes, and then it starts decreasing. Complex II becomes the dominant species after 90
minutes (ca. 45%)and increases to ca. 70% of the overall reaction products after 4 hours.
The solution reaches a steady composition within 24 h. Free acyclovir (8.5%) is present in
the final reaction mixture in which 83% of total ACV is present as compound II, and 8.5%
as compound I. All the trans-Ru substrate has been consumed by the end of the reaction.
The reaction progress observed using, a slight excess of the ruthenium substrate
(ACV:trans-Ru r 1:1,25) was very similar to that of r (Fig. c). However under
these conditions the monoadduct remains the dominant species even at the end of the
reaction (after 1 day). This seems reasonable since the ligand concentration is now even
smaller than that of the Ru substrate. It is also worth noting that the percentage of
bisadduct is still significantly high notwithstanding the excess of metallic substrate over the
acyclovir ligand.
The reaction of acyclovir with trans-Ru has also been performed at 37 C (Figure 2).
It proceeds much faster (ca 10 times) than the corresponding reaction carried out at ambient
temperature but the ratio of the products at the end of the reaction is similar.
In all the _experiments performed with trans-Ru the final spectra exhibit two single
resonances at i5 8.85 and 8.58 ppm in the region of H8 resonances, belonging to
compounds I and II, respectively (Fig. 3, Table I).
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Figure 2. Time dependence ofthe concentration of different species in the reaction of trans-
Ru with ACV (ACV:trans-Ru 2:1) at 37 in water solvent. The concentrations were
determined by integration of the peak areas of the aromatic region (H8 of ACV) in the H
NMR spectra.
The large downfield shifts of H8 (0,92 and 0,65 ppm for compounds I and II,
respectively) are typical of N7 coordination of the guanine moiety to a transition metal
center. This was previously observed for the complexes of trans-Ru with guanine bases.
Specifically, the reaction of trans-Ru with 2’-dGuo [17, 18] leads to the formation of two
dastereoisomeric monoadducts and a bisadduct, in which the guanosine is coordinated to
Ru via NT. In the case of reaction of trans-Ru with 5’-dGMP [19] again two
diastereoisomeric monoadducts are formed in which the nucleotide coordinates to the metal
center through N(7) of the purine moiety and an oxygen of the phosphate group.
H8 HI’
II
9.0 8.5 8.0 5.6 5.4
ppm ppm
Figure 3. Sections of the IH NMR spectra at different time intervals (a, 0 min; b, 40 min; c,
80 min; d, 24 h) of the reaction mixture ACV:trans-Ru 1:1, at room temperature and D20
solvent. The peaks of unreacted ACV are denoted with an asterisk (*).
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Table I: H NMR (& solvent D20) of ACV, hydrolyzed trans-Ru and cis-Ru, and their
complexes.
Compound
ACV
trans-Ru
1
cis-Ru
Ru(DMSO)3Clz(H20)]+ Ru(DMSO)3CI(H20)2]
H(8) H(I’) H(2’) H(3’) DMSO
7.93 5.51 3.67 3.67
3.49, 3.47, 3.39
3.50, 3.43, 3.39
3.44, 3.36,a 3.26 Compound I 8.85 5.66 3.73 3.73
Compound II 8.58 5.55 m, ,,,,b 3.49 m 3.63 rn 3.35 3.21
a The signal at 3.36 ppm, which however overlaps with the signal at 3.35 ofcompound II,
appears to have twice the intensity of the signals at 3.44 and 3.26 ppm.
b rn multiplet.
Reaction with d(GpG) leads to the formation of a stable compound with two N(7)-
coordinated guanine moieties [20]. Bifunctional coordination was also found for the
dinucleotides GpA, ApG, d(ApG) and d(GpA) [21] where the two purine bases are
coordinated to ruthenium through N(7). The same coordination mode was obseLved for 9-
ethylguanine (9-EtG) when reacted with Ru(II) compounds giving [RuClz(I-C6H6)(9
The proposed reaction route is depicted in Scheme 2.
151 151
iH /S -2DMSO S. R!/OH2 -CI" S..R,u./OH2
SSI
Fast lOH21 OH21
+ACV 1
+ ACV
CI OH OH
R!
ACV CI Sl
ACV +ACV S.__RIu"
ACV _
u
S lOH21
J OH21 ACVI
Intermedmte Compound Compound
Scheme2. Proposed mechanism for the reaction of trans-[RuC12(DMSO)4] with ACV in
water solution. S S-bonded DMSO. The overall charge of the complexes is not indicated,
it is 0 for species containing two chlorine ligands and +1 for species containing only one
chlorine ligand.
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The H(1 ’) protons of the monoadduct appear as a singlet at 5 5.66 ppm (Fig. 3). In
the same region (5.57 ppm) the H(I’) atoms of the bisadduct appear as an AB quartet
indicating that the C(I’)H2 protons are not equivalent but undergo a diastereotopic splitting
of ca. 0.1 ppm. The non-equivalence of the C(1 ’)Hz protons is characteristic ofa bisadduct
with the two ACV ligands in cis positions and can originate from a restricted rotation of the
alkyl chain about the C(I’)-N(9) bond and of the two coordinated acyclovir molecules
about the N(7)-Ru bonds. The H(2’) and H(3’) protons also appear as a singlet in the
monoadduct and as multiplets in the bisadduct.
The DMSO methyl signals partially overlap with the H(2’) and H(3 ) resonances of
the disubstituted compound. In order to identify unequivocally the peaks of the DMSO
ligands the spectra were compared with those obtained using the fully deuterated trans-Ru
species. On this ground the two equally intense resonances at 3.42 and 3.25 ppm and a
resonance at 3.36 ppm, partially overlapping with one signal ofcompound II and having an
intensity twice the ntensity of the signals at 3.44 and 3.26 ppm, (Table I) were assigned to
the DMSO methyl groups belonging to the monoadduct, while another set of two equally
intense signals at 3.20 and 3.34 ppm was assigned to the DMSO methyl protons of the
bisadduct. Evidence that the DMSO ligands are bound through the S atom s provided by
the fact that there is a small difference in the chemical shifts of the DMSO protons of the
hydrolyzed trans-Ru species and those of compounds I and II.
In addition to the complexed species, also the methyl signals of hydrolyzed trans-Ru
species, trans, cis, cis.-[RuClz(H20)z(DMSO)z] (3.35 ppm) and fac, cis-
[RuCI(HzO)3(DMSO)2]* (3.38 and 3.37 ppm), and of free DMSO (2.72 ppm) were
observed in the cases of r 1:1 and 1:1.25.
The assignments of the 3C NMR spectra of the two compounds are reported in
Table II. A considerable downfield shift of C(8) (monoadduct +4.8, bisadduct +4.2 ppm)
confirms the formation of Ru-N(7) bonds. Negligible shifts were observed for the alkyl
chain carbons, C(I’), C(2’) and C(3’), confirming the non involvement in the metal
coordination of either the ether oxygen or the hydroxyl group.
Table II" 3C NMR (5, solvent D20) ofACV, hydrolyzed trans-Ru, and their complexes.
Compound
ACV (in D20)
ACV (in DMSO-d6)
a
trans-Ru
[Ru(DMSO)2C12(H20)2]
[Ru(DMSO)2CI(HzO)3]
+
C(6) C(2) C(4) C(8) C(5) C(I’)C(2’)C(3’)DMSO
141.9 74.8 72.2 62.3
160.8 157.8 155.4 141.7 120.4 76.0 74.4 63.9
CompoundI 160.4 156.0 154.9 146.7 117.5 74.3 72.1 61.6
Compound II 159.9 155.9 154.6 146.1 117.2 74.7 71.8 61.5
44.6
44.0
45.8
45.6
46.2
45.8
45.2
45.0
From reference 28
The DMSO methyl peaks in the 3C NMR spectra also confima the findings of the
H NMR spectra. Two resonances were observed for each one of the reaction products.
The difference in chemical shifts were comparable to that observed for the two carbon
resonances of the cationfac, cis-[RuCl(H20)3(DMSO)2]+.
Reaction of cis-[RuCI2(DMSO)4] with acyclovir
The reaction of cis-[RuClz(DMSO)4] with acyclovir, in water solution, was
monitored by NMR and the appearance of the different species as a function of time is
depicted in Fig. 4. Two products are formed also in this case, they exhibit H NMR spectra
identical to those of the compounds obtained in the previous reaction of the trans-Ru
isomer with ACV.
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Figure 4. Time dependence of the concentration of different species in the reaction of cis-
Ru with ACV (a, ACV’cis-Ru 1"1; b, ACV:cis-Ru 2"1; c, ACV:cis-Ru 1"1.25)
performed in water solution at room temperature. The concentrations were determined by
integration of the peak areas of the aromatic region (H8 ofACV) in the H NMR spectra.
The kinetic profiles observed in the reactions of cis-Ru with acyclovir differ from
those observed for the trans-Ru isomer. When the reactions are carried on at room
temperature the solution reaches a steady composition after 40 50 hour reaction time. In
all cases the bisadduct is the compound that dominates after the first hour of reaction. The
concentration of the monoadduct increases during the first 5 hours reaching about 20% of
the overall ACV species present in solution. At the end of the reaction the bisadduct
accounts for about 70% of the total for r 1"1 or 1"1.25, while at a molar ratio of 2:1 it
0 reaches about 80 of the total ACV species.
The reaction of acyclovir with cis-Ru has also been recorded at 37 C for r 1 and 2.
The rates are much faster (ca. 10 times) but the type and concentration f products are the
same as those observed at ambient temperature.
It is worth noting that in all the reactions performed with the cis-Ru complex, the
concentration of complex I in the initial stage of the reaction never increases above that at
the end of the reaction, contrary to what has been observed in all reactions performed with
trans-Ru (Fig. 1 a-1 c) where the concentration of complex I reaches a maximum in the early
stage of the reaction and then decreases.
As mentioned earlier, the 1H NMR spectra of the two reaction products,
(compounds I and II) obtained in the reaction of acyclovir with cis-Ru are exactly the same
as those obtained in the reaction of acyclovir with trans-Ru. However, during the progress
of the reaction, the DMSO methyl region is different, reflecting the different hydrolysis
products of cis-Ru as compared to those of trans-Ru [5, 16]. Fig. 5 reports the reaction
progress in the case of ambient temperature and using a slight excess of metal substrate (r
1"1.25).
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Figure 5. Sections of the HNMR spectra at different time intervals (a, 0 h; b, h; c, 2,5 h,
d, 8 h; e, 29 h) of the reaction mixture ACV:cis-Ru 1:1.25, at room temperature and D20
solvent. The peaks of unreacted ACV are indicated with a circle (o).
0 OH OH
S.
Cl DMSO S OH2 H2 OH2 / DMSO u
+ ACV 1
+ACV
ACV ACV ACV
R[ OH2 +ACV H20".I
S OH2 _DMSO H2 /
ACV
u/ u
Intermediate Compound Compound 11
Scheme3. Proposed mechanism for the reaction ofcis-[RuC12(DMSO)] with ACV in water
solution. S S-bonded DMSO, O O-bonded DMSO. The overall charge of the complexes
is not indicated, it is 0 for species containing two chlorine ligands and +1 for species
containing only one chlorine ligand.
In the reaction of cis-Ru with 5’-GMP [29], the 8uanine N(7) and a phosphate
oxygen both bind to Ru(II) and form a chelate with the metal center. Such a chelate does not
form in the case of acyclovir due to the much poorer coordination ability of the hydroxyl
group as compared to that of a phosphate. As a consequence the monoadduct reacts further
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with an acyclovir molecule to give the bisadduct. Similarly the major product in the reaction
of cis-Ru with the dinucleotides GpA, ApG, d(ApG), and d(GpA) [21] was a
disubstituted compound in which both purines of the dinucleotides were coordinated to the
metal through theN(7) atoms.
The proposed reaction route for the cis-Ru isomer is depicted in Scheme 3.
The formation ofcomplex I appears to be faster in the case of the trans-Ru complex
as compared to that of the cis isomer. This might imply that in both cases the reactive
species is the diaqua complex which is formed immediately after dissolution in water in the
case of the trans-Ru complex, while it is formed more slowly in the case of the cis-Ru
isomer. The conversion ofthe monoadduct into the bisadduct presumably takes place with
the same rate in the two cases (this is true also in the light of the same identity of
complexes I and II in the two cases). As a consequence in the case of trans-Ru there is
accumulation ofmonoadduct in the initial stage of tlae reaction, afterwards the concentration
of monoadduct decreases because it reacts with a second molecule of ACV to give the
bisadduct. In the case of cis-Ru such an accumulation is not observed because of the smaller
rate of formation of the monoadduct.
It is also to be noted that, substitution of one and two solvent molecules by ACV
ligands in the diaqua species of trans-Ru and cis-Ru would lead to mono- and di-substituted
species differing in the nature ofthe axial ligands (two chlorides in the former case and one
chloride and one DMSO in the latter case). The obtainment of identical species in both
cases implies that meanwhile the reaction progresses hydrolysis of one axial ligand (CI in
trans-Ru and DMSO in cis-Ru) leads to identical species containing one chloride and one
solvent molecule in axial positions. Such a solvolysis of an axial ligand has been taken into
account in drawing Schemes 2 and 3. The slowerrate of formation of the monoadduct in the
cis-Ru complex also accounts for the relatively smaller concentration of monoadduct (with
respect to the bisadduct) at the end of the reaction.
CONCLUSIONS
The present investigation, apart from confirming the analogy in the coordination
behavior of acyclovir with respect to other guanine bases, has also underlined some
substantial differences between the behavior of antitumoral platinum(II) and ruthenium(II)
complexes. These differences are: i) Greaterpropensity of the ruthenium(II) complexes to
give the bis-adducts as compared to monoadducts. Under similar experimental conditions
(e. g. use of an excess of metal substrate with respect to the purine ligand) platinum(II)
substrates would have given, almost exclusively, the monoadduct, ii) Analogy in the
behavior of the cis and the trans isomers of the ruthenium(II) complex which give exactly
the same mono and bisadducts independently from the different coordination geometry of
the starting substrate. This is not the case of platinum(II) species which give different
reaction products depending upon the cis or trans geometry of the starting substrate. These
results may be relevant to the different antitumor activity of platinum and the ruthenium
substrates.
Although giving similar products, the rate of formation of the monoadduct is higher in
the case of the trans-Ru complex as compared to that of the cis-Ru isomer. This might
imply that in both cases the reactive species is the diaqua complex. This would aso
account for the greater propensity of the ruthenium substrates to give the bisadduct as
compared to the platinum substrates.
An investigation of the antiviral and antitumoral activities of the ruthenium adducts
with acyclovir (both the mono and the bis derivatives) is under way. It will be interesting tq
compare the results with those already obtained for the antiviral and anticancer activity of
the platinum complexes with acyclovir.
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